Get the Stockscreener App
0.0769
0.00%
0.00
Hepion Pharmaceuticals Inc stock is traded at $0.0769, with a volume of 5,105.
It is up +0.00% in the last 24 hours and up +2.53% over the past month.
See More
Previous Close:
$0.0769
Open:
$0.0769
24h Volume:
5,105
Relative Volume:
0.13
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-2.98M
P/E Ratio:
-0.2969
EPS:
-0.259
Net Cash Flow:
$-1.71M
1W Performance:
+8.23%
1M Performance:
+2.53%
6M Performance:
+47.88%
1Y Performance:
+39.31%
1-Day Range:
$0.0769
$0.0769
1-Week Range:
$0.0625
$0.0805
52-Week Range:
$0.0341
$0.1052
Hepion Pharmaceuticals Inc Stock (HEPA) Company Profile
Name
Hepion Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare HEPA vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HEPA
Hepion Pharmaceuticals Inc
|
0.0769 | 0 | 0 | -2.98M | -1.71M | -0.259 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hepion Pharmaceuticals Inc Stock (HEPA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-20-20 | Resumed | ROTH Capital | Buy |
Hepion Pharmaceuticals Inc Stock (HEPA) Latest News
Insiders holding 51% of Hepion (HEPA) back reverse split and 750M-share increase - Stock Titan
Hepion (NASDAQ: HEPA) grants director 299,000 options at $0.08 - Stock Titan
Hepion Pharmaceuticals Secures Funding via Convertible Note Agreement - TipRanks
Hepion Pharmaceuticals Raises $500,000 Via 8% Secured Convertible Note With Gravitas, 12.5M Warrants - TradingView
Hepion Pharmaceuticals stock trades quietly as investors watch liver disease pipeline - ad-hoc-news.de
Major holders back Hepion (HEPA) reverse split, share increase - Stock Titan
Hepion Pharmaceuticals Inc. (HEPA) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Hepion Pharmaceuticals Announces New Private Placement Financing - TipRanks
Hepion Raises $400,000 in Private Placement at $0.05, Issues Five-Year Warrants at $0.06 - TradingView
Hepion Pharmaceuticals Inc. (HEPA) Peer Comparison – Compare with Others - Value Research
CTRVP SEC FilingsHepion Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Hepion (HEPA) grants interim CEO 1.35M options at $0.08 - Stock Titan
Hepion chair granted 1.35M options at $0.08 | HEPA Insider Trading - Stock Titan
Hepion Pharmaceuticals (HEPA) gives VP 1.35M options at $0.08 - Stock Titan
Hepion (HEPA) director awarded 299K stock options - Stock Titan
Hepion Pharmaceuticals (HEPA) awards director 299K stock options - Stock Titan
Hepion Pharmaceuticals (HEPA) awards 299K options to director - Stock Titan
Hepion Pharmaceuticals Appoints James Liddy to Board of Directors - Minichart
Hepion appoints James Liddy to its board - TradingView
Hepion (NASDAQ: HEPA) COO locks in 2M warrants at $0.06 - Stock Titan
Hepion (HEPA) chairman-led group builds 26M-share stake - Stock Titan
Black Global 5 Llc Net Worth (2026) - GuruFocus
Wednesday’s insider buys and sells: Hepion insiders invest $800K By Investing.com - Investing.com Nigeria
Hepion Pharmaceuticals, Inc. Q2 2026: Revenue $0 Net loss $(1.25M), EPS $(0.08) — 10-Q Summary - TradingView
Hepion Pharmaceuticals director Stetz buys $25,000 in common stock By Investing.com - Investing.com Nigeria
Hepion Pharmaceuticals interim CEO Gary Stetz buys $100,000 in stock By Investing.com - Investing.com Nigeria
Hepion Pharmaceuticals director Michael Purcell buys $100,000 in stock By Investing.com - Investing.com Australia
Hepion Pharmaceuticals director Stetz buys $25,000 in common stock - Investing.com
Hepion Pharmaceuticals interim CEO Gary Stetz buys $100,000 in stock - Investing.com
Hepion COO Sireesh Appajosyula buys $100,000 in common stock By Investing.com - Investing.com Nigeria
Hepion COO Sireesh Appajosyula buys $100,000 in common stock - Investing.com
Hepion Pharmaceuticals executive chairman LoPriore buys $500,000 in stock - Investing.com
Hepion Pharmaceuticals executive chairman LoPriore buys $500,000 in stock By Investing.com - Investing.com India
Hepion Pharmaceuticals (HEPA) director purchases 500K shares and 500K warrants - Stock Titan
Hepion Pharmaceuticals (NASDAQ: HEPA) director purchases 2M shares and 2M warrants - Stock Titan
Hepion Pharmaceuticals (HEPA) interim CEO Stetz buys 4M shares and warrants - Stock Titan
Hepion Pharmaceuticals (HEPA) chair LoPriore reports 20M-share and warrant purchases - Stock Titan
Hepion Pharmaceuticals (HEPA) holder reports 10M warrants and 10M shares - Stock Titan
Darin Feinstein Discloses Investment at Hepion Pharmaceuticals with 11.1% Stake - TradingView
Investor buys 10M Hepion Pharmaceuticals (HEPA) shares plus warrant - Stock Titan
Hepion Pharmaceuticals (HEPA) completes $3.06M exempt securities sale under Rule 506(b) - stocktitan.net
Hepion Pharmaceuticals, Inc. announced that it has received $3.055 million in funding - marketscreener.com
Hepion Pharmaceuticals, Inc. Revenue Breakdown – OTC:HEPA - TradingView
Hepion Pharmaceuticals, Inc. Revenue Breakdown – OTC:CTRVP - TradingView
Hepion Pharmaceuticals (HEPA) Proxy Filing Summary - Quartr
Hepion Pharmaceuticals (HEPA) Proxy filing Summary - Quartr
Hepion Pharmaceuticals (HEPA) Q4 2025 earnings summary - Quartr
Hepion Pharmaceuticals (HEPA) director Stetz submits initial insider Form 3 - Stock Titan
Hepion Pharmaceuticals (HEPA) director Danina Fisher files initial Form 3 - Stock Titan
Hepion Pharmaceuticals Inc Stock (HEPA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.88%
Cap:
|
Volume (24h):